Beta Bionics, Inc. (BBNX) Stock Forecast
BBNX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.33 / 5 from 15 analysts
- Price target
- $24.24 average of analyst targets
- Upside to target
- +48.3% from the latest close
- Next earnings
- October 27, 2026 EPS estimate $-0.53
- 52-week range
- $8.86 – $31.99
BBNX analyst ratings
15 analystsNumber of analysts at each rating.
BBNX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BBNX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.51 | −$0.55 | −$0.46 | −$0.33 | −55.5% | 3 |
| Current fiscal year (2026) | −$1.88 | −$2.06 | −$1.61 | −$1.38 | −36.4% | 3 |
| Next fiscal year (2027) | −$2.16 | −$2.49 | −$1.83 | −$1.88 | −14.9% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BBNX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $34.6M | $34.0M | $35.4M | +26.9% | 10 |
| Current fiscal year (2026) | $124.4M | $122.0M | $126.0M | +24.1% | 10 |
| Next fiscal year (2027) | $182.6M | $169.9M | $192.0M | +46.9% | 14 |
BBNX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BBNX revenue: reported and forecast
BBNX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.53 | −$0.51 | −$0.51 | −$0.49 | −$0.51 | −2.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.11 | −$1.90 | −$1.90 | −$1.83 | −$1.88 | −10.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.39 | −$2.31 | −$2.31 | −$2.33 | −$2.16 | −9.6% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BBNX earnings surprises
Reported EPS vs the consensus estimate for the last 8 quarters; BBNX beat in 5 of 8.
What analysts expect from BBNX
15 analysts cover Beta Bionics; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $24.24, 48.3% above the latest close of $16.35. Analysts expect earnings of −$1.88 per share for 2026, −36.4% from a year earlier. For 2027 the average estimate is −$2.16 per share on revenue of $182.6 million. Beta Bionics beat the EPS estimate in 5 of the last 8 quarters.
Related: BBNX income statement, BBNX key metrics, BBNX chart. See the BBNX stock overview for the latest quote and news.
BBNX forecast FAQ
What is Beta Bionics's price target?
The average analyst price target for Beta Bionics is $24.24, 48.3% above the latest close of $16.35.
Is Beta Bionics a buy, hold or sell?
Of 15 analysts covering Beta Bionics, 9 rate it a strong buy, 2 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Beta Bionics's EPS forecast?
Analysts forecast −$1.88 per share for 2026 (range −$2.06 to −$1.61); for 2027 the estimate is −$2.16.
What is Beta Bionics's revenue forecast?
The average revenue estimate for 2026 is $124.4 million, growth of 24.1%; for 2027 it is $182.6 million.
When does Beta Bionics report earnings?
Beta Bionics is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 after the market closes; the EPS estimate is $-0.53.
Does Beta Bionics usually beat earnings estimates?
Beta Bionics reported EPS at or above the analyst estimate in 5 of the last 8 quarters.